Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,998 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

NCT04515238

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Hamatologische/Onkologische Gemeinschaftspraxis Augsburg, Germany
  • Universitätsklinik Köln Cologne, Germany
  • Onkologische Schwerpunktpraxis Esslingen am Neckar, Germany
  • Evangelische Krankenhaus Hamm Hamm, Germany
View Trial Details
Active, not recruiting

A Study of Enasidenib in People With T-Cell Lymphoma

NCT06756308

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, not recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
Locations
  • Yale University New Haven, Connecticut, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • Ucsf Fresno University of California San Francisco Fresno Fresno, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
  • Cancer and Blood Specialty Clinic Los Alamitos, California, United States
  • Los Angeles Cancer Network Los Angeles, California, United States
View all 266 locations
View Trial Details
Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

NCT02390869

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • ASST Grande Ospedale Metropolitano Niguarda Milan, MI, Italy
  • AUSL di Ravenna Ravenna, RA, Italy
  • Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo Candiolo, Torino, Italy
  • Ospedale S. Giacomo di Castelfranco Veneto Castelfranco Veneto, Treviso, Italy
View all 28 locations
View Trial Details
Active, not recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

NCT03876769

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations
  • Children s Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • City of Hope National Medical Duarte, California, United States
  • Childrens Hospital Los Angeles Los Angeles, California, United States
View all 43 locations
View Trial Details
Active, not recruiting

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +16 more
Locations
  • Concord Repatriation General Hospital /ID# 201261 Concord, New South Wales, Australia
  • Anhui Provincial Cancer Hospital /ID# 209458 Hefei, Anhui, China
  • Peking University People's Hospital /ID# 156575 Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital /ID# 156579 Fuzhou, Fujian, China
View all 31 locations
View Trial Details

Related conditions